Trials
1 active
3 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression, Post-Natal Depression, Peripartum Depression
- Main trialPhase 3
- “The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD). The trial aims to determine: * If LPCN 1154A reduces depressive symptoms in subjects with severe PPD * How well LPCN 1154A is tolerated and what side effects it may cause”In the company’s words, NCT07822321 on ClinicalTrials.gov
- Other names
- Brexanolone
Coming up1
- Aug 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | Aug 2027 | Brexanolone Lifting Outcomes Of Moms | |
| Phase 3Completed | 16 Jan 2026 | A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | |
| Phase 1Ended | not given | A Randomized, Double-blind, Double Placebo-controlled, 4-Period Crossover Study to Evaluate the Central Nervous System Pharmacodynamic Activity of Brexanolone Using Transcranial Magnetic Stimulation in Healthy Male Participants |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026